180 related articles for article (PubMed ID: 28718043)
1. Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry.
Harrold LR; John A; Best J; Zlotnick S; Karki C; Li Y; Greenberg JD; Kremer JM
Clin Rheumatol; 2017 Sep; 36(9):2135-2140. PubMed ID: 28718043
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry.
Harrold LR; Reed GW; Magner R; Shewade A; John A; Greenberg JD; Kremer JM
Arthritis Res Ther; 2015 Sep; 17(1):256. PubMed ID: 26382589
[TBL] [Abstract][Full Text] [Related]
3. Impact of Tocilizumab Monotherapy on Clinical and Patient-Reported Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis.
Harrold LR; John A; Reed GW; Haselkorn T; Karki C; Li Y; Best J; Zlotnick S; Kremer JM; Greenberg JD
Rheumatol Ther; 2017 Dec; 4(2):405-417. PubMed ID: 28936808
[TBL] [Abstract][Full Text] [Related]
4. EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.
Gülfe A; Wallman JK; Kristensen LE
Arthritis Res Ther; 2016 Feb; 18():51. PubMed ID: 26892115
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Rituximab for the Treatment of Rheumatoid Arthritis in Patients with Prior Exposure to Anti-TNF: Results from the CORRONA Registry.
Harrold LR; Reed GW; Shewade A; Magner R; Saunders KC; John A; Kremer JM; Greenberg JD
J Rheumatol; 2015 Jul; 42(7):1090-8. PubMed ID: 25934829
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.
Harrold LR; Reed GW; Solomon DH; Curtis JR; Liu M; Greenberg JD; Kremer JM
Arthritis Res Ther; 2016 Dec; 18(1):280. PubMed ID: 27906048
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial.
Manders SH; Kievit W; Adang E; Brus HL; Moens HJ; Hartkamp A; Hendriks L; Brouwer E; Visser H; Vonkeman HE; Hendrikx J; Jansen TL; Westhovens R; van de Laar MA; van Riel PL
Arthritis Res Ther; 2015 May; 17(1):134. PubMed ID: 25997746
[TBL] [Abstract][Full Text] [Related]
8. Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis.
Walker UA; Jaeger VK; Chatzidionysiou K; Hetland ML; Hauge EM; Pavelka K; Nordström DC; Canhão H; Tomšič M; van Vollenhoven R; Gabay C
Rheumatology (Oxford); 2016 Feb; 55(2):230-6. PubMed ID: 26316581
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
Keystone EC; Taylor PC; Tanaka Y; Gaich C; DeLozier AM; Dudek A; Zamora JV; Cobos JAC; Rooney T; Bono S; Arora V; Linetzky B; Weinblatt ME
Ann Rheum Dis; 2017 Nov; 76(11):1853-1861. PubMed ID: 28798049
[TBL] [Abstract][Full Text] [Related]
10. Benefit of biologics initiation in moderate versus severe rheumatoid arthritis: evidence from a United States registry.
Kavanaugh A; Keystone E; Greenberg JD; Reed GW; Griffith JM; Friedman AW; Saunders KC; Ganguli A
Rheumatology (Oxford); 2017 Jul; 56(7):1095-1101. PubMed ID: 28340006
[TBL] [Abstract][Full Text] [Related]
11. Comparative responsiveness of the EuroQol-5D and Short Form 6D to improvement in patients with rheumatoid arthritis treated with tumor necrosis factor blockers: results of the Dutch Rheumatoid Arthritis Monitoring registry.
Buitinga L; Braakman-Jansen LM; Taal E; Kievit W; Visser H; van Riel PL; van de Laar MA
Arthritis Care Res (Hoboken); 2012 Jun; 64(6):826-32. PubMed ID: 22262513
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.
Schiff M; Takeuchi T; Fleischmann R; Gaich CL; DeLozier AM; Schlichting D; Kuo WL; Won JE; Carmack T; Rooney T; Durez P; Shaikh S; Hidalgo RP; van Vollenhoven R; Zerbini CAF
Arthritis Res Ther; 2017 Sep; 19(1):208. PubMed ID: 28923098
[TBL] [Abstract][Full Text] [Related]
13. Treatment with the first TNF inhibitor in rheumatoid arthritis patients in the Hellenic Registry of Biologic Therapies improves quality of life especially in young patients with better baseline functional status.
Boubouchairopoulou N; Flouri I; Drosos AA; Boki K; Settas L; Zisopoulos D; Skopouli FN; Papadopoulos I; Iliopoulos A; Kyriopoulos J; Boumpas DT; Athanasakis K; Sidiropoulos P
Clin Exp Rheumatol; 2016; 34(6):999-1005. PubMed ID: 27749220
[TBL] [Abstract][Full Text] [Related]
14. Disease activity and patient-reported outcomes in patients with rheumatoid arthritis and Sjögren's syndrome enrolled in a large observational US registry.
Harrold LR; Shan Y; Rebello S; Kramer N; Connolly SE; Alemao E; Kelly S; Kremer JM; Rosenstein ED
Rheumatol Int; 2020 Aug; 40(8):1239-1248. PubMed ID: 32449040
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial.
van Riel PL; Freundlich B; MacPeek D; Pedersen R; Foehl JR; Singh A;
Ann Rheum Dis; 2008 Aug; 67(8):1104-10. PubMed ID: 17666447
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry.
Kavanaugh A; Lee SJ; Curtis JR; Greenberg JD; Kremer JM; Soto L; Etzel CJ; Cox V; Yoshida K; Reed GW; Solomon DH
Ann Rheum Dis; 2015 Jun; 74(6):1150-5. PubMed ID: 25471471
[TBL] [Abstract][Full Text] [Related]
17. Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry.
Rotar Z; Hočevar A; Rebolj Kodre A; Praprotnik S; Tomšič M;
Clin Rheumatol; 2015 Oct; 34(10):1787-93. PubMed ID: 26345633
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis.
Sung YK; Cho SK; Kim D; Choi CB; Won S; Bang SY; Cha HS; Choe JY; Chung WT; Hong SJ; Jun JB; Kim HA; Kim J; Kim SK; Kim TH; Lee HS; Lee J; Lee J; Lee SS; Lee SW; Lee YA; Nah SS; Suh CH; Yoo DH; Yoon BY; Bae SC;
Rheumatol Int; 2017 Jun; 37(6):975-982. PubMed ID: 28132102
[TBL] [Abstract][Full Text] [Related]
19. Safety of rituximab in the routine treatment of rheumatoid arthritis in Italy in patients refractory to anti-TNFa drugs: results from the observational retrospective-prospective RUBINO study.
Bazzichi L; Biasi D; Tinazzi E; Muratore M; Pellerito R; Russo R; Corsaro Santi M; De Sandre P; Epis O; Granata M; Kroegler B; Meschini C; Versace F; Astolfi C;
Reumatismo; 2014 Nov; 66(3):224-32. PubMed ID: 25376957
[TBL] [Abstract][Full Text] [Related]
20. Improvement in patient-reported outcomes after rituximab in rheumatoid arthritis patients: An open-label assessment of 175 patients.
Gossec L; Danré A; Combe B; Le Loët X; Tebib J; Sibilia J; Mariette X; Dougados M
Joint Bone Spine; 2015 Dec; 82(6):451-4. PubMed ID: 26162632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
